CN1778366A - Medicine composition for hypertension and its preparation thereof - Google Patents
Medicine composition for hypertension and its preparation thereof Download PDFInfo
- Publication number
- CN1778366A CN1778366A CN 200510071146 CN200510071146A CN1778366A CN 1778366 A CN1778366 A CN 1778366A CN 200510071146 CN200510071146 CN 200510071146 CN 200510071146 A CN200510071146 A CN 200510071146A CN 1778366 A CN1778366 A CN 1778366A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- fructus
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An enterior-applied Chinese medicine for treating hypertension is prepared from 10 Chinese-medicinal materials including prepared rehmannia root, astragatus root, wolfberry fruit, tangerine, etc.
Description
Technical field
The present invention relates to hypertensive pharmaceutical composition of a kind of treatment and preparation method thereof, relating in particular to a kind of is the hypertensive Chinese patent medicine of treatment that feedstock production forms with the Chinese herbal medicine, belongs to the field of Chinese medicines.
Background technology
Hypertension is a kind of commonly encountered diseases frequently-occurring disease, the Chang Keyin rupture of blood vessel in brain and cause Hemorrhagic strokes or because of the supply heart coronary thrombosis cause serious consequences such as cardiac dysfunction, myocardial infarction, coronary heart disease, cerebral thrombosis.China's hypertension prevalence obviously rises, estimate according to relevant department, China more than 15 years old the hypertension number of patients reached more than 9,000 ten thousand, estimated also can increase more than 60% by 2010, according to present fashion trend investigation, the control form allows of no optimist, and China has become one of the most serious country of hypertension harm in the world.
Three big old complaints of hypertension are: 1, and secular chronic gastroenteritis, 2, cause the cardiorenal function quality low by the reason of chronic gastroenteritis, make irritability lose pharmacy, pathogenic wind rises.3, the reason by 1 and 2 causes big cerebral oxygen supply blood supply poorness initiation cerebrovascular to circulate smooth or expands and the initiation dizziness, and feeling of fullness in the head is had a headache.Again since each individual first day after tomorrow body quality and the four seasons change different, its patient's blood pressure performance is also inequality.Be categorized as: two high diseases (being that high hypotension is all high), low high disease (being that high pressure is normal or higher, the low pressure height), the normal single high disease of high pressure high-low pressure, high pressure height, the low anti-high disease of forcing down.Because the difference of blood pressure performance, its internal organs root is because of also inequality with the treatment prescription.
Though the hypertensive method of treatment is a lot of at present, but because this sick pathogeny is comparatively complicated, great majority adopt medicine, massage, acupuncture, spirit etc. to carry out comprehensive therapy and have obtained curative effect preferably, though hypertensive complication has been played the better controlled effect, but certain dependency is arranged, be unfavorable for fundamentally eliminating disease.
Have a variety ofly though be used for the treatment of hypertensive medicine at present, certain curative effect also all arranged in clinical use, all in various degree have that side effect is big, curative effect is definite inadequately, can not treating both the principal and secondary aspects of a disease etc. defective.
Summary of the invention
Technical problem to be solved by this invention is to overcome the deficiencies in the prior art, provides a kind of treatment evident in efficacy, treating both the principal and secondary aspects of a disease hypertensive pharmaceutical composition.
Technical problem to be solved by this invention realizes by following technological approaches:
The hypertensive pharmaceutical composition of a kind of treatment comprises that following bulk drugs makes:
10～25 parts in Radix Rehmanniae Preparata, 8～20 parts of ERXIANJIAO, 8～20 parts of the Rhizoma Atractylodis Macrocephalaes, 6～15 parts of Radix Paeoniae Alba, 10～25 parts of the Radixs Astragali, 9～15 parts in the Radix Rehmanniae, 9～15 parts of FRUCTUS LYCII, 5～15 parts of Pericarpium Citri Reticulataes, 5～15 parts of the Rhizoma Pinelliaes, 2～8 parts of Radix Ginsengs.
Be preferably: 18 parts in Radix Rehmanniae Preparata, 15 parts of ERXIANJIAO, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Radix Paeoniae Alba, 18 parts of the Radixs Astragali, 12 parts in the Radix Rehmanniae, 12 parts of FRUCTUS LYCII, 9 parts of Pericarpium Citri Reticulataes, 9 parts of the Rhizoma Pinelliaes, 4 parts of Radix Ginsengs.
In order to reach better therapeutic, medicine of the present invention also can contain following bulk drugs: 6～12 parts of Flos Lonicerae, 6～12 parts of Rhizoma Coptidis; 6～12 parts of Fructus Forsythiaes, 6～12 parts of Herba Schizonepetae, 6～12 parts of Rhizoma Phragmitiss; 5～10 parts of Semen Coiciss, 5～10 parts of Fructus Gardeniaes, 5～10 parts of Rhizoma Et Radix Notopterygiis; 5～10 parts of Radix Angelicae Pubescentiss, 5～10 parts of Radix Saposhnikoviaes, 5～10 parts of Rhizoma Chuanxiongs; 5～10 parts of Calculus Boviss, 5～10 parts in Cinnabaris, 5～10 parts of Realgars; 5～10 parts of Fructus Viticises, 5～10 parts of Radix Platycodoniss, 5～10 parts of the Radixs Angelicae Dahuricae; 5～10 parts of Cortex Magnoliae Officinalis, 5～10 parts in Radix Glycyrrhizae, 5～10 parts of Rhizoma Atractylodis; 4～8 parts of Ramulus Cinnamomi, 4～8 parts of Rhizoma Alismatis, 4～8 parts of Radix Curcumaes; 4～8 parts of Fructus Aurantii Immaturuss; 4～8 parts in Herba Ephedrae, 4～8 parts in Poria, 4～8 parts of Borneolum Syntheticums; 4～8 parts of Radix Paeoniae Rubra; 4～8 parts of Cortex Moutans, adenine phosphate～8 part, 2～4 parts of FUFANG JIANGYA PIAN; 2～6 parts of Willow bark; 2～6 parts of Folium Populi Pseudo-simonii, 2～6 parts in Natrii Sulfas, 2～6 parts of Radix Et Rhizoma Rhei; 2～6 parts of Semen Pharbitidiss; 2～6 parts on Cornu Bovis seu Bubali, 2～6 parts of Pheretimas, 2～6 parts in Rhizoma Gastrodiae; 2～6 parts of Fructus Choerospondiatis core; 2～6 parts of Semen Platycladi, 2～6 parts of Radix Angelicae Sinensis, 2～6 parts of rhizoma sparganic; 2～6 parts of the Radix Aucklandiae; 2～6 parts of the Cortexs Eucommiae, 2～6 parts of Massa Medicata Fermentatas, 2～6 parts of Carapax Trionycis.
The weight portion of each crude drug is more preferably in the pharmaceutical formulation of the present invention:
18 parts in Radix Rehmanniae Preparata, 15 parts of ERXIANJIAO, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Radix Paeoniae Alba, 18 parts of the Radixs Astragali; 12 parts in the Radix Rehmanniae, 12 parts of FRUCTUS LYCII, 9 parts of Pericarpium Citri Reticulataes, 9 parts of the Rhizoma Pinelliaes, 4 parts of Radix Ginsengs; 9 parts of Flos Lonicerae, 9 parts of Rhizoma Coptidis, 9 parts of Fructus Forsythiaes, 9 parts of Herba Schizonepetae, 9 parts of Rhizoma Phragmitiss; 7 parts of Semen Coiciss, 7 parts of Fructus Gardeniaes, 7 parts of Rhizoma Et Radix Notopterygiis, 7 parts of Radix Angelicae Pubescentiss, 7 parts of Radix Saposhnikoviaes; 7 parts of Rhizoma Chuanxiongs, 7 parts of Calculus Boviss, 7 parts in Cinnabaris, 7 parts of Realgars, 7 parts of Fructus Viticises; 7 parts of Radix Platycodoniss, 7 parts of the Radixs Angelicae Dahuricae, 7 parts of Cortex Magnoliae Officinalis, 7 parts in Radix Glycyrrhizae, 7 parts of Rhizoma Atractylodis; 6 parts of Ramulus Cinnamomi, 6 parts of Rhizoma Alismatis, 6 parts of Radix Curcumaes, 6 parts of Fructus Aurantii Immaturuss, 6 parts in Herba Ephedrae; 6 parts in Poria, 6 parts of Borneolum Syntheticums, 6 parts of Radix Paeoniae Rubra, 6 parts of Cortex Moutans, 6 parts of vitamin Bs; 3 parts of FUFANG JIANGYA PIAN, 4 parts of Willow bark, 4 parts of Folium Populi Pseudo-simonii, 4 parts in Natrii Sulfas, 4 parts of Radix Et Rhizoma Rhei; 4 parts of Semen Pharbitidiss, 4 parts on Cornu Bovis seu Bubali, 4 parts of Pheretimas, 4 parts in Rhizoma Gastrodiae; 4 parts of Fructus Choerospondiatis core, 4 parts of Semen Platycladi, 4 parts of Radix Angelicae Sinensis, 4 parts of rhizoma sparganic; 4 parts of the Radix Aucklandiae, 4 parts of the Cortexs Eucommiae, 4 parts of Massa Medicata Fermentatas, 4 parts of Carapax Trionycis.
Pharmaceutical composition of the present invention is based on hypertensive differential diagnosis of diseases of Chinese medicine and the dialectical principle that combines, treating both the principal and secondary aspects of a disease, deficiency and excess is also controlled, reinforce insufficiency and reduce excessiveness, filter out that suppressing the hyperactive liver and subsiding YANG, clearing away fire and eliminating phlegm, YIN nourishing are supported kidney, benefiting vital QI and blood, spasmolytic voltage stabilizing, demountable natural plant nourishes blood, according to the theory of Chinese medical science prescription, be prepared from according to certain weight proportion.
This prescription is selected formulated from the multiple natural vegetable Chinese herbal medicine with good lowering and stabilizing blood pressure effect, its mechanism of curing the disease is by correcting the regulating blood pressure material balance, remove the spasm of vascular smooth muscle and impel the expansion of toy blood vessel, make peripheral vascular resistance reduce, thereby improved blood circulation, make blood pressure return to normal value, its maximum characteristics can make the body abnormal hemodynamics correct voluntarily exactly, thereby make body regulation and control blood pressure machine make basic recovery, solved the drawback that common drug can only take stopgap measures fully, can also improve and strengthen the function of heart and other vitals in the hypertensive while of treatment, and can eliminate the dizziness insomnia that causes because of hypertension, limbs fatigue, symptoms such as the easy agitation of lassitude, played the hypertensive effect of Comprehensive Treatment, can make the patient remove slight illness in a short time, its biggest advantage can reach exactly fundamentally alleviates hypertension, blood pressure is steadily descended afterwards be difficult for ging up again.
Pharmaceutical composition of the present invention adds various conventional adjuvant required when preparing different dosage form, for example disintegrating agent, lubricant, adhesive etc. are prepared into any oral preparations commonly used with the method for Chinese medicinal of routine, for example can be pill, capsule, tablet, powder, granule or oral liquid etc.Be preferably capsule.
The used herbal raw material of the present invention all can be buied from the Chinese medicine shop, and its specification meets national medical standard.
Usage and consumption: dosage of the present invention depends on concrete dosage form, factors such as patient's age, body weight, health status.As guidance: for oral administration: 1) capsule: obey every day three times, obey 2～3 at every turn, every content of dispersion 0.4g, warm water takes.2) tablet: obey every day three times, obey 2～4 at every turn, every content of dispersion 0.4g, warm water takes.3) pill: obey every day three times, obey 8g at every turn, warm water takes.
The specific embodiment
Further describe the present invention by the following examples, it should be understood that these embodiment only are used for the purpose of illustration, never limit the scope of the invention.
The preparation of [embodiment 1] capsule
By following weight take by weighing each raw material (unit: g):
Radix Rehmanniae Preparata 18, ERXIANJIAO 15, the Rhizoma Atractylodis Macrocephalae 15, Radix Paeoniae Alba 10, the Radix Astragali 18, the Radix Rehmanniae 12, FRUCTUS LYCII 12, Pericarpium Citri Reticulatae 9, the Rhizoma Pinelliae 9, Radix Ginseng 4; Grind into after each component mixing with above-mentioned weight and incapsulate promptly after fine powder is crossed 1500 mesh sieves.
The preparation of [embodiment 2] granule
By following weight take by weighing each raw material (unit: g):
Radix Rehmanniae Preparata 10, ERXIANJIAO 8, the Rhizoma Atractylodis Macrocephalae 8, Radix Paeoniae Alba 6, the Radix Astragali 10, the Radix Rehmanniae 9, FRUCTUS LYCII 9, Pericarpium Citri Reticulatae 5, the Rhizoma Pinelliae 5, Radix Ginseng 2.Each raw material of above-mentioned weight is mixed, after grinding into fine powder and crossing 1500 mesh sieves, add ethanol and make adhesive, add starch and make filler, be pressed into granule.
The preparation of [embodiment 3] tablet
By following weight take by weighing each raw material (unit: g):
Radix Rehmanniae Preparata 25, ERXIANJIAO 20, the Rhizoma Atractylodis Macrocephalae 20, Radix Paeoniae Alba 15, the Radix Astragali 25, the Radix Rehmanniae 15; FRUCTUS LYCII 15, Pericarpium Citri Reticulatae 15, the Rhizoma Pinelliae 15, Radix Ginseng 8, Flos Lonicerae 12, Rhizoma Coptidis 12; Fructus Forsythiae 12, Herba Schizonepetae 12, Rhizoma Phragmitis 12, Semen Coicis 10, Fructus Gardeniae 10, Rhizoma Et Radix Notopterygii 10; Radix Angelicae Pubescentis 10, Radix Saposhnikoviae 10, Rhizoma Chuanxiong 10, Calculus Bovis 10, Cinnabaris 10, Realgar 10; Fructus Viticis 10, Radix Platycodonis 10, the Radix Angelicae Dahuricae 10, Cortex Magnoliae Officinalis 10, Radix Glycyrrhizae 10, Rhizoma Atractylodis 10; Ramulus Cinnamomi 8, Rhizoma Alismatis 8, Radix Curcumae 8, Fructus Aurantii Immaturus 8, Herba Ephedrae 8, Poria 8; Borneolum Syntheticum 8, Radix Paeoniae Rubra 8, Cortex Moutan 8, VB8, FUFANG JIANGYA PIAN 4, Willow bark 6; Folium Populi Pseudo-simonii 6, Natrii Sulfas 6, Radix Et Rhizoma Rhei 6, Semen Pharbitidis 6, Cornu Bovis seu Bubali 6; Pheretima 6, Rhizoma Gastrodiae 6, Fructus Choerospondiatis core 6, Semen Platycladi 6, Radix Angelicae Sinensis 6; rhizoma sparganic 6, the Radix Aucklandiae 6, the Cortex Eucommiae 6, Massa Medicata Fermentata 6, Carapax Trionycis 6.Each raw material of above-mentioned weight is mixed, after grinding into fine powder and crossing 1500 mesh sieves, make granule, and dry compacting in flakes promptly.
The preparation of [embodiment 4] pill
By following weight take by weighing each raw material (unit: g):
Radix Rehmanniae Preparata 18, ERXIANJIAO 15, the Rhizoma Atractylodis Macrocephalae 15, Radix Paeoniae Alba 10, the Radix Astragali 18, the Radix Rehmanniae 12; FRUCTUS LYCII 12, Pericarpium Citri Reticulatae 9, the Rhizoma Pinelliae 9, Radix Ginseng 4, Flos Lonicerae 9, Rhizoma Coptidis 9; Fructus Forsythiae 9, Herba Schizonepetae 9, Rhizoma Phragmitis 9, Semen Coicis 7, Fructus Gardeniae 7, Rhizoma Et Radix Notopterygii 7; Radix Angelicae Pubescentis 7, Radix Saposhnikoviae 7, Rhizoma Chuanxiong 7, Calculus Bovis 7, Cinnabaris 7, Realgar 7; Fructus Viticis 7, Radix Platycodonis 7, the Radix Angelicae Dahuricae 7, Cortex Magnoliae Officinalis 7, Radix Glycyrrhizae 7, Rhizoma Atractylodis 7; Ramulus Cinnamomi 6, Rhizoma Alismatis 6, Radix Curcumae 6, Fructus Aurantii Immaturus 6, Herba Ephedrae 6, Poria 6; Borneolum Syntheticum 6, Radix Paeoniae Rubra 6, Cortex Moutan 6, vitamin B 6, FUFANG JIANGYA PIAN 3, Willow bark 4; Folium Populi Pseudo-simonii 4, Natrii Sulfas 4, Radix Et Rhizoma Rhei 4, Semen Pharbitidis 4, Cornu Bovis seu Bubali 4; Pheretima 4, Rhizoma Gastrodiae 4, Fructus Choerospondiatis core 4, Semen Platycladi 4, Radix Angelicae Sinensis 4; rhizoma sparganic 4, the Radix Aucklandiae 4, the Cortex Eucommiae 4, Massa Medicata Fermentata 4, Carapax Trionycis 4.Each raw material of above-mentioned weight is mixed, after grinding into fine powder and crossing 80～200 mesh sieves, make pill promptly.
The clinical observation on the therapeutic effect test of [test example 1] pharmaceutical composition of the present invention
One, clinical data
Observe case and be the out-patient, amount to 287 examples, wherein male 162 examples, women 125 examples, 28～75 years old age, 41 years old mean age.
Two, trial drug
For the reagent thing: the capsule that the embodiment of the invention 1 is prepared.
Three, Therapeutic Method
Oral for reagent thing, each 2,3 times on the one.15 days is a course of treatment, treats 3 courses of treatment altogether.
Four, curative effect determinate standard
1, produce effects medication 5 days obviously improves with interior symptom, Signs, and integration reduces 〉=70%.
2, effectively medication 5 days reduces 〉=30% with interior symptom, sign integration.
3, invalid medication 5 days does not have obvious improvement with interior symptom and sign, or integration reduces less than 30%.
Five, observed result
The total effective rate of hypertension therapy of the present invention is 100%, and wherein obvious effective rate is 91.7%, and effective percentage is 8.3%.Clinical drug safety is not observed any untoward reaction, clinical drug safety.
The explanation of clinical trial observed result, pharmaceutical composition of the present invention has significant clinical efficacy for hypertension, and determined curative effect, instant effect have no side effect.
Claims (7)
1, the hypertensive pharmaceutical composition of a kind of treatment, comprise that following bulk drugs makes: 10～25 parts in Radix Rehmanniae Preparata, 8～20 parts of ERXIANJIAO, 8～20 parts of the Rhizoma Atractylodis Macrocephalaes, 6～15 parts of Radix Paeoniae Alba, 10～25 parts of the Radixs Astragali, 9～15 parts in the Radix Rehmanniae, 9～15 parts of FRUCTUS LYCII, 5～15 parts of Pericarpium Citri Reticulataes, 5～15 parts of the Rhizoma Pinelliaes, 2～8 parts of Radix Ginsengs.
2, according to the pharmaceutical composition of claim 1, it is characterized in that the weight portion of each crude drug is: 18 parts in Radix Rehmanniae Preparata, 15 parts of ERXIANJIAO, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Radix Paeoniae Alba, 18 parts of the Radixs Astragali, 12 parts in the Radix Rehmanniae, 12 parts of FRUCTUS LYCII, 9 parts of Pericarpium Citri Reticulataes, 9 parts of the Rhizoma Pinelliaes, 4 parts of Radix Ginsengs.
3; according to the pharmaceutical composition of claim 1, it is characterized in that including following bulk drugs: 6～12 parts of Flos Lonicerae, 6～12 parts of Rhizoma Coptidis; 6～12 parts of Fructus Forsythiaes, 6～12 parts of Herba Schizonepetae, 6～12 parts of Rhizoma Phragmitiss; 5～10 parts of Semen Coiciss, 5～10 parts of Fructus Gardeniaes, 5～10 parts of Rhizoma Et Radix Notopterygiis; 5～10 parts of Radix Angelicae Pubescentiss, 5～10 parts of Radix Saposhnikoviaes, 5～10 parts of Rhizoma Chuanxiongs; 5～10 parts of Calculus Boviss, 5～10 parts in Cinnabaris, 5～10 parts of Realgars; 5～10 parts of Fructus Viticises, 5～10 parts of Radix Platycodoniss, 5～10 parts of the Radixs Angelicae Dahuricae; 5～10 parts of Cortex Magnoliae Officinalis, 5～10 parts in Radix Glycyrrhizae, 5～10 parts of Rhizoma Atractylodis; 4～8 parts of Ramulus Cinnamomi, 4～8 parts of Rhizoma Alismatis, 4～8 parts of Radix Curcumaes; 4～8 parts of Fructus Aurantii Immaturuss; 4～8 parts in Herba Ephedrae, 4～8 parts in Poria, 4～8 parts of Borneolum Syntheticums; 4～8 parts of Radix Paeoniae Rubra; 4～8 parts of Cortex Moutans, 4～8 parts of vitamin Bs, 2～4 parts of FUFANG JIANGYA PIAN; 2～6 parts of Willow bark; 2～6 parts of Folium Populi Pseudo-simonii, 2～6 parts in Natrii Sulfas, 2～6 parts of Radix Et Rhizoma Rhei; 2～6 parts of Semen Pharbitidiss; 2～6 parts on Cornu Bovis seu Bubali, 2～6 parts of Pheretimas, 2～6 parts in Rhizoma Gastrodiae; 2～6 parts of Fructus Choerospondiatis core; 2～6 parts of Semen Platycladi, 2～6 parts of Radix Angelicae Sinensis, 2～6 parts of rhizoma sparganic; 2～6 parts of the Radix Aucklandiae; 2～6 parts of the Cortexs Eucommiae, 2～6 parts of Massa Medicata Fermentatas, 2～6 parts of Carapax Trionycis.
4,, it is characterized in that being prepared into any suitable oral formulations by Chinese medicine conventional formulation method according to the pharmaceutical composition of claim 1.
5,, it is characterized in that described preparation is pill, capsule, tablet, powder, granule, drop pill or suppository according to the pharmaceutical composition of claim 4.
6,, it is characterized in that described preparation is a capsule according to the pharmaceutical composition of claim 5.
7, the purposes of the described arbitrary pharmaceutical composition of claim 1～6 in preparation treatment hypertension drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100711466A CN100342891C (en) | 2005-05-20 | 2005-05-20 | Medicine composition for hypertension and its preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100711466A CN100342891C (en) | 2005-05-20 | 2005-05-20 | Medicine composition for hypertension and its preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1778366A true CN1778366A (en) | 2006-05-31 |
| CN100342891C CN100342891C (en) | 2007-10-17 |
Family
ID=36768903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100711466A Expired - Fee Related CN100342891C (en) | 2005-05-20 | 2005-05-20 | Medicine composition for hypertension and its preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100342891C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032619B (en) * | 2007-02-02 | 2010-05-19 | 贾聚宝 | Liquid medicine to be taken orally for curing primary hypertension and the preparing method |
| CN102670958A (en) * | 2012-04-28 | 2012-09-19 | 朱凤华 | Chinese medicine powder for treating cerebral thrombosis and hypertension |
| CN103690834A (en) * | 2013-12-30 | 2014-04-02 | 广西梧州制药（集团）股份有限公司 | Antihypertensive traditional Chinese medicinal composition and preparation method thereof |
| CN103751449A (en) * | 2013-12-25 | 2014-04-30 | 奉娟 | Traditional Chinese medicinal composition for hypertension reduction assistance and preparation method thereof |
| CN103977191A (en) * | 2014-06-06 | 2014-08-13 | 任杰 | Traditional Chinese medicine for treating hypertension |
| CN104082670A (en) * | 2014-07-09 | 2014-10-08 | 朱路英 | Health porridge with effect of lowering blood pressure and production method thereof |
| CN106075106A (en) * | 2016-08-27 | 2016-11-09 | 朱保群 | A kind of Chinese medicine composition treating hypertension and preparation method thereof |
| CN109106891A (en) * | 2018-09-25 | 2019-01-01 | 安徽兆龙食品有限公司 | It is a kind of to absorb fast biological agent and preparation method thereof |
| CN115770280A (en) * | 2021-09-07 | 2023-03-10 | 大连未康生物技术有限公司 | Pressure-stabilizing dropping liquid |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106979B (en) * | 2011-02-18 | 2012-05-02 | 周秀尧 | Medicament for treating hypertension |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090765A (en) * | 1993-02-12 | 1994-08-17 | 张祥德 | " Shouwuchangchunbao " medicine containing polygonum multiflorum and preparation method thereof |
| CN1240429C (en) * | 2002-05-16 | 2006-02-08 | 杨文志 | Poison expelling and astheniz resisting balance pill and its preparing method |
-
2005
- 2005-05-20 CN CNB2005100711466A patent/CN100342891C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032619B (en) * | 2007-02-02 | 2010-05-19 | 贾聚宝 | Liquid medicine to be taken orally for curing primary hypertension and the preparing method |
| CN102670958A (en) * | 2012-04-28 | 2012-09-19 | 朱凤华 | Chinese medicine powder for treating cerebral thrombosis and hypertension |
| CN103751449A (en) * | 2013-12-25 | 2014-04-30 | 奉娟 | Traditional Chinese medicinal composition for hypertension reduction assistance and preparation method thereof |
| CN103690834A (en) * | 2013-12-30 | 2014-04-02 | 广西梧州制药（集团）股份有限公司 | Antihypertensive traditional Chinese medicinal composition and preparation method thereof |
| CN103977191A (en) * | 2014-06-06 | 2014-08-13 | 任杰 | Traditional Chinese medicine for treating hypertension |
| CN104082670A (en) * | 2014-07-09 | 2014-10-08 | 朱路英 | Health porridge with effect of lowering blood pressure and production method thereof |
| CN106075106A (en) * | 2016-08-27 | 2016-11-09 | 朱保群 | A kind of Chinese medicine composition treating hypertension and preparation method thereof |
| CN109106891A (en) * | 2018-09-25 | 2019-01-01 | 安徽兆龙食品有限公司 | It is a kind of to absorb fast biological agent and preparation method thereof |
| CN115770280A (en) * | 2021-09-07 | 2023-03-10 | 大连未康生物技术有限公司 | Pressure-stabilizing dropping liquid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100342891C (en) | 2007-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342891C (en) | Medicine composition for hypertension and its preparation thereof | |
| CN1840128A (en) | Medicine for treating cardiovascular disease | |
| CN1814208A (en) | Oral Chinese medicine for treating and preventing recurrence of uecerative stomatitis | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN1486740A (en) | Chinese medicine composition for treating cancer | |
| CN101637559B (en) | Instant oral liquid for kidney stone | |
| CN101579492A (en) | Medicine for treating high blood pressure and preparation method thereof | |
| CN103127326A (en) | Pharmaceutical composition for treating osteoarthritis and preparation method thereof | |
| CN102813814B (en) | Traditional Chinese medicine formula for treating hypotension | |
| CN102579610B (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN104491733A (en) | Application of traditional Chinese medicine preparation in preparation of medicines for treating anemia, deficiency of vital energy and debilitation | |
| CN101041006A (en) | Composite Chinese medicine took orally for treating coronary heart disease | |
| CN100450520C (en) | Medicine for treating chronic glomerular nephritis and its producing method | |
| CN101411801A (en) | Method for preparing Chinese medicinal composition for anti-abortion and formulation thereof | |
| CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN103585414B (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
| CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
| CN102423368A (en) | Chinese medicinal composition for treating sequelae of cerebral thrombosis and cerebral hemorrhage, as well as preparation method thereof | |
| CN101549057A (en) | Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same | |
| CN104857441A (en) | Oral preparation for treating femoral head necrosis and preparation method of oral preparation | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN102824461A (en) | Medicine for treating hypertension and preparation method thereof | |
| CN100434103C (en) | Chinese medicine composition for treating anemogenous-ache disease | |
| CN1316989C (en) | Capsule with dried human placemta and red sage root and its preparing process | |
| CN102225132A (en) | Traditional Chinese medicine compound for treating hyperlipidaemia, cerebral arteriosclerosis and ischemic stroke and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071017 Termination date: 20100520 |